Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Published byAlberta Rogers Modified over 8 years ago

Similar presentations

Presentation on theme: "Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110."— Presentation transcript:

1 Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110 1 MCF-7MCF-7/DOX ** * A 0 20 40 60 80 100 120 MDA-MB-231 Cell Proliferation (% Con) MCF-7 MCF-7/DOX T47D 0520 DOX (μM) 0520 05 05 ** MCF-7MCF-7/DOX ― + DOX (1 μ M) ― + PARP (uncleaved) PARP (cleaved) Tubulin

2 Figure 2 B 0 10 20 30 40 50 60 MCF-7MCF-7/DOX Invasion (No. of cells/HPF) * A CD 0 20 40 60 80 100 Lung tumors/ mouse (%) MCF-7MCF-7/DOX * P < 0.001 uPA MMP-9 MMP-2 MCF-7MCF-7/DOX

3 A B ControlNS398 0 20 40 60 80 100 120 0102550 NS398 ( μ M) Cell Proliferation (% Con) Invasion (No. of cells/% control) Figure 3 C Cox-2 Actin MDA-MB-231 MCF-7 MCF-7/DOX T47D 0 20 40 60 80 100 120 Control NS398 (50 μ M) * uPA MMP-9 MMP-2 NS398 ( μ M) 0 10 25 50 D E Migration (No. of cells/% control) 0 20 40 60 80 100 120 * Cox-2 : siRNA SCR

4 Figure 4 E Gefitinib ( μ M) EGF– + + – – 2 Actin pEGFR Cox-2 EGFR C 0 2 4 8 12h EGF EGFR Actin Cox-2 SCR EGFR SCR EGFR : siRNA EGFR Tubulin Cox-2 B A D Gefitinib EGFR Tubulin MDA-MD-231 MCF-7/DOX Invasion (No. of cells/% control) 0 20 40 60 80 100 120 Control MDA-MB-231 MCF-7 MCF-7/DOX T47D ` 20 40 60 80 100 120 Gefitinib ( μ M) – 2 Cell Proliferation (% Con) 0 – 2 *

5 ControlLY294002 Cell Proliferation (% Con) AB C D – + EGF 0 20 40 60 80 100 120 ControlU0126 U0126 ( μ M) – – 5 10 – + + + EGF Actin Cox-2 pERK1/2 Actin Cox-2 ERK 1/2 pERK 1/2 Akt pAkt LY294002 ( μ M) – 10 pAkt LY294002 ( μ M) – + + – – 10 Actin Cox-2 EGF Invasion (No. of cells/% control) 0 20 40 60 80 100 120 * – 10 Invasion (No. of cells/% control) 0 20 40 60 80 100 120 – 10 U0126 ( μ M) Cell Proliferation (% Con) ` 20 40 60 80 100 120 – 10 0 * Figure 5 E SCR Cox-2 : siRNA Actin Cox-2 F MMP-9 MMP-2 GAPDH uPA Cox-2SCR : siRNA U0126 Control LY294002 U0126 Control LY294002 MMP-9 MMP-2 GAPDH uPA RT-PCR WB

6 Figure 6 AB DC SCREP1 EP3 : siRNA EP1 EP3 SCR : siRNA 0 20 40 60 80 100 120 140 Invasion (No. of cells/% control) SCR EP1 siRNA * EP1 : siRNA SCR MMP-2 MMP-9 uPA β-Actin MCF-7 MCF-7/DOX EP1 EP2 EP3 EP4 PGE 2 – + EP1 EP2 EP3 EP4 β-Actin 0 20 40 60 80 100 120 140 SCR EP3 siRNA * EP1 EP3 – + – – – – – + – – – – – + + – – – – + PGE 2 17-PT-PGE2 Sulprostone AH6809 GAPDH uPA MMP2 MMP9 E

7

Download ppt "Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110."

Similar presentations

ScrMMP-1 Supplementary Fig. 1, Ganguly et al. 0 25 50 75 100 ScrMMP-3 ScrMMP-3MT1-MMP 100 m Relative Invasion 0 25 50 75 100 Scr MMP-1 100 m abc Scr Scr.

ScrMMP-1 Supplementary Fig. 1, Ganguly et al ScrMMP-3 ScrMMP-3MT1-MMP 100 m Relative Invasion Scr MMP m abc Scr Scr.
Cell number (% vehicle control) cisplatin concentration (µM)gefitinib concentration (µM) 10 1 10 2 10 3 cell number expression level (fluorescence intensity)

Cell number (% vehicle control) cisplatin concentration (µM)gefitinib concentration (µM) cell number expression level (fluorescence intensity)
00.111000.1110 A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S1 0.004.01.040.01.030.10.313100.01.11.

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S
Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE1965.810.7 WI380.131.9 MCF10A16.751.9 HCT116115.3177.6 HCT116.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.
NPV-BEZ235PKI-587 GDC-0980PD0325901 Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD0325901.

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD
Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.

Supplimental figure 1. Melanoma free survival curve (A) and summary table (B) for median survival and melanoma free survival for each genotype. All of.
Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.

Effects of declining sorafenib levels and dose on acquired reversible resistance and toxicity in hepatocellular carcinoma Elizabeth A. Kuczynski, Christina.
The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.

The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.
WT KO A B Suppl. Fig 1 Supplemental Figure 1. The expression of CYLD in liver. (A) Immunohistochemical analysis of CYLD in liver tissue of adult wildtype.

WT KO A B Suppl. Fig 1 Supplemental Figure 1. The expression of CYLD in liver. (A) Immunohistochemical analysis of CYLD in liver tissue of adult wildtype.
Supplemental Figure S2. Location and H 2 O 2 -dependent binding of RBPs to biotinylated MKP-1 transcripts. (A) Schematic of the MKP-1 mRNA showing the.

Supplemental Figure S2. Location and H 2 O 2 -dependent binding of RBPs to biotinylated MKP-1 transcripts. (A) Schematic of the MKP-1 mRNA showing the.
Herceptin + 17-AAG Combination BT-474 Tumors

Herceptin + 17-AAG Combination BT-474 Tumors
Journal title: Autophagy Induction by Capsaicin in Malignant Human Breast Cells is Modulated by p38 and ERK Mitogen-Activated Protein Kinases and Retards.

Journal title: Autophagy Induction by Capsaicin in Malignant Human Breast Cells is Modulated by p38 and ERK Mitogen-Activated Protein Kinases and Retards.
Marker (%) Normal EPCs Mean ± SM (%) MMD EPCs Mean ± SM (%) CD3426.9 ± 11.531.0 ± 6.8 KDR27.3 ± 5.5222.4 ± 8.90 CD13324.5 ± 4.6412.6 ± 3.93 CD3199.0 ±

Marker (%) Normal EPCs Mean ± SM (%) MMD EPCs Mean ± SM (%) CD ± ± 6.8 KDR27.3 ± ± 8.90 CD ± ± 3.93 CD ±
Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.
Additional File 1 A. p38 (38 kDa) shRNA Control p53 (53 kDa) shRNA p53 B. Untransfected cells Relative cell no. GFP- vector GFP-Ras G12V Fluorescence Additional.

Additional File 1 A. p38 (38 kDa) shRNA Control p53 (53 kDa) shRNA p53 B. Untransfected cells Relative cell no. GFP- vector GFP-Ras G12V Fluorescence Additional.
Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.

Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.
Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC3 0 100 200 300 400 500 % of Viable Cells  AGR2(nM) 0 10 100.

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)
0 4 8 12 24 48 (hr) Cleaved Caspase-9 Caspase-8 100 nM Paclitaxel MCF-7 Figure S1a.

(hr) Cleaved Caspase-9 Caspase nM Paclitaxel MCF-7 Figure S1a.
A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) 0 5 10 20 Stat3:Stat3 % of Cont 100 56 43 1 Supplementary Figures Fig. S1 -

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

Similar presentations

Ads by Google